Results 181 to 190 of about 2,223,665 (257)

Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression. [PDF]

Front Oncol
Shi Y, Chen F, Weng Y, Zeng H, Chen G.
europepmc   +1 more source

Knockdown of RPL28 Inhibits the Progression of Clear Cell Renal Cell Carcinoma

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive histological subtype of kidney cancer. Previous studies have implicated ribosomal protein L28 (RPL28) in the progression of various cancers; however, its role in ccRCC remains unclear.
Runbiao Luo, Guozhong Wu, Zhouzhou Xie, Yuchen Xiao, Wenbiao Zhu, Huiming Jiang   +5 more
wiley   +1 more source

Comprehensive In Silico Analysis Identifies MSTO1 and LIG1 as Candidate Biomarkers With Diagnostic and Prognostic Relevance in Hepatocellular Carcinoma

Cancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and remains a major cause of cancer‐related mortality worldwide. Its poor clinical outcomes are largely attributed to late‐stage diagnosis and the limited accuracy of currently available diagnostic and prognostic biomarkers.
Jana Hamad, Hussein Fayyad‐Kazan, Fadi Abdel‐Sater   +2 more
wiley   +1 more source

GRB2 Promotes Sorafenib Resistance in Hepatocellular Carcinoma Cells Under Hypoxia by Activating the PI3K/AKT Signaling Pathway. [PDF]

J Hepatocell Carcinoma
He J, Kong Y, Wang Y, Fang Q, Wu H, Du K, Luo Y, Tan J, Yin H, Lin H, Li M.   +10 more
europepmc   +1 more source

Urethral Metastasis of Therapy‐Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report

IJU Case Reports, Volume 9, Issue 5, September 2026.
ABSTRACT Introduction Urethral metastasis of prostate cancer is exceptionally rare, particularly in castration‐resistant disease. Therapy‐induced neuroendocrine prostate cancer (t‐NEPC) is an aggressive variant with limited treatment options. Case Presentation A 72‐year‐old man, 14 years after diagnosis of prostate adenocarcinoma treated with androgen ...
Toshiaki Kayaba, Satoshi Washino, Takanori Hayase, Kai Yazaki, Kimitoshi Saito, Tomoaki Miyagawa   +5 more
wiley   +1 more source

CHAF1B: the hidden culprit behind sorafenib resistance in hepatocellular carcinoma. [PDF]

Int J Med Sci
Zhuo W, Zhao J, Zheng Z, Cai S, Zeng G, Lin E, Bai Z, Wang B, Jia Y, Li P, Li J.   +10 more
europepmc   +1 more source

Ferroptosis: Newly Emerged Regulator for Human Disease

MedComm, Volume 7, Issue 9, September 2026.
Ferroptosis is a key regulated cell death pathway closely involved in cancers, neurodegenerative disorders, acute organ injuries, and cardiovascular and chronic metabolic diseases, representing a promising therapeutic target for diverse human illnesses.
Dandan Xiao, Lin Ye, Tianqi Jiang, Mengyuan Liu, Yuxia Zhou   +4 more
wiley   +1 more source

RhoE downregulation leads to enhanced cholesterol biosynthesis and sorafenib resistance in hepatocellular carcinoma. [PDF]

J Biol Chem
Feng J, Ye L, Chen C, Zhu Y, Liu R, Yu H, Lu L, Gong K, Li W.   +8 more
europepmc   +1 more source

Advances in FGF/FGFR Signaling: Implications for Disease and Therapy

MedComm, Volume 7, Issue 9, September 2026.
The FGF/FGFR signaling is indispensable for the maintenance of physiological homeostasis and governs multiple biological processes, including embryonic development, bone metabolism, angiogenesis, and neurogenesis, whereas aberrant hyperactivation of this pathway drives the progression of malignancies and autoimmune disorders, including inflammatory ...
Miaoyu Song, Xi Liu, Yang Xiao, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

Disrupting CARMA3 Signaling with Triptolide Reverses Sorafenib Resistance in Hepatocellular Carcinoma. [PDF]

Int J Med Sci
Wang WY, Hsu TW, Su YH, Su CM, Wang TH, Chiu CF, Tsai KY, Huang CY, Chen HA, Liao PH.   +9 more
europepmc   +1 more source